SOTIO to Present New Data from Phase 1 Study of IL-15 Superagonist, SOT101


SOTIO to Present New Data from Phase 1 Study of IL-15 Superagonist, SOT101, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

November 3, 2021 Source: Press Release, Basel


  • SOTIO will present three posters discussing data that highlight the encouraging safety and efficacy for SOT101 (SO-C101) as a monotherapy and in combination with pembrolizumab for the treatment of advanced solid tumors.

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced that it will present three posters highlighting new clinical data on SOT101 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting to be held virtually and in person, from November 10-14, 2021 in Washington, D.C.

SOT101 is an interleukin 15 (IL-15) superagonist currently being evaluated in an open-label Phase 1/1b study to evaluate the safety and preliminary efficacy as a monotherapy and in combination with pembrolizumab in patients with selected relapsed/refractory advanced/metastatic solid tumors. Details on the upcoming presentations are below:

Poster presentation details:

Title: Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors

Poster Number: 484 Session: In-Progress Clinical Trials Presenting Author: Elena Garralda, M.D. Date: Saturday, November 13

Title: Recommended phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the IL-15 superagonist SO-C101 as monotherapy in patients with advanced/metastatic solid tumors

Poster Number: 502 Session: In-Progress Clinical Trials Presenting Author: Marabelle Aurelien M.D., Ph.D. Date: Saturday, November 13

Title: SO-C101, a high-affinity IL-15R agonist, induces safe and potent anti-tumor immune activities in patients with solid tumors and supports further clinical investigations.

Poster Number: 510 Session: In-Progress Clinical Trials Presenting Author: Lenka Palová Jelínková, Ph.D. Date: Saturday, November 13

Selected presentation materials will be made available on the SOTIO Biotech website once the presentations conclude.


About SOT101:

SOT101 (formerly SO-C101 or RLI-15) is a subcutaneously-administered IL-15 superagonist that is fused to the sushi+ domain of the IL-15 receptor α chain. SOT101 has demonstrated strong preclinical in vivo efficacy in various tumor models showing increased long-term survival and tumor regression, as well as a favorable toxicology profile. SOT101 has been shown in pre-clinical models to synergize with checkpoint inhibitors and antibody therapies exerting ADCC.

11 views0 comments